| Name | Title | Contact Details |
|---|
Trio Health offers a unique collaboration with clinical experts, patients and specialty pharmacies to allow unparalleled insight into patient care. Together with our advisory boards, we created Trio Health MDX, a proprietary system to collect and share information from all three stakeholders. This innovative collaboration provides the patient with unprecedented care thereby improving patient outcomes.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
MAKE AN APPOINTMENT Adult: 210.261.1250 Children: 210.261.3350 The Center for Health Care Services (CHCS) is proud to present our Annual Report for Fiscal Year 2018. By making Our People, Our Community, Our Priority; CHCS is changing lives, restoring...
Millennium Laboratories is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.